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Abstract We showed previously that the calcium-dependent
protease, calpain, cleaves the cytoplasmic domain of the integrin
L3 subunit. To investigate whether susceptibility to calpain is a
common feature of all integrin L subunits, and to map calpain
cleavage sites in different integrin L tails, we treated recombinant
cytoplasmic domains of integrin L1A, L1D, L2, L3 and L7
subunits with purified calpain in vitro. We found that the
cytoplasmic domains of all these integrin chains were cleaved by
calpain. HPLC followed by mass spectrometry was used to
identify calpain cleavage sites. These sites were clustered in the
C-terminal half of the integrin L cytoplasmic domains in regions
flanking the two NXXY motifs, suggesting the possibility that
the structural framework provided by these motifs is recognized
by calpain. We used the knowledge of these cleavage sites to
develop cleavage site-specific antibodies and to demonstrate
cleavage of the L1A cytoplasmic domain in intact platelets
stimulated with calcium ionophore or thrombin. Thus suscept-
ibility to calpain cleavage is common to integrin L subunits, can
be induced in intact cells, and appears to favor regions
surrounding two conserved NXXY motifs.
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1. Introduction
Calpains, a family of intracellular cysteine endopeptidases
(EC 3.4.22.17), are ubiquitously distributed in animal cells
and tissues (for review, see [1^4]). The two classical members
of this family, m- and W-calpain, present a highly similar, if
not identical substrate speci¢city, but di¡er in the amounts of
calcium required for their activation in vitro [1,4]. In addition
to intracellular calcium levels, the activity of these calpains is
tightly regulated by a natural cytosolic inhibitor, calpastatin,
as well as by plasma membrane-binding activator proteins and
certain phospholipids indicating an important role of mem-
brane association in calpain activation [3,5]. Cleavage sites
generated by these enzymes are characterized by a high var-
iation in the amino acids adjacent to the scissile bond [1,4].
Therefore, susceptibility to cleavage by calpains is not primar-
ily determined by the linear amino acid sequence at one scis-
sile bond, but rather by other structural features, which are
not fully understood.
Many cellular substrates of calpains are cytoskeletal pro-
teins [1] and regulatory proteins implicated in the formation
of focal adhesions, e.g. pp125FAK [6], pp60src [7] or paxillin
[8]. Together with the earlier ¢nding of calpain immunolocal-
ization in focal adhesions of certain cell lines [9], this has led
to the concept that calpains could play a regulatory role in the
turnover of focal adhesions [10]. Furthermore, ¢brinogen
binding to platelet integrin KIIbL3 triggers rapid W-calpain
translocation to the membrane [11], where it is activated
and cleaves cytoskeletal proteins such as ¢lamin, talin, and
spectrin [3]. Moreover, our laboratory recently provided evi-
dence that platelet aggregation coincides with calpain-depend-
ent proteolysis of the integrin L3 cytoplasmic domain [12].
Cleavage occurred in membrane-distal regions of the integrin
L3 tail at sites £anking the two NXXY motifs. These motifs
are conserved in most integrin L cytoplasmic domains and are
crucial for integrin-mediated signal transduction and for their
interactions with the cytoskeleton [13^15]. We therefore asked
whether calpains can cleave other integrin cytoplasmic do-
mains as well. Here we report that calpains can cleave integrin
L1A, L1D, L2, L3 and L7 tails between and adjacent to their
NPXY/NXXY motifs. Furthermore, using cleavage site-spe-
ci¢c anti-L1A antibodies, we detect calpain-dependent pro-
teolysis in intact platelets. Thus, calpains recognize and cleave
a common structural framework in integrin L tails in vivo.
2. Materials and methods
2.1. Synthetic peptides and puri¢ed proteins
Puri¢ed m-calpain (80 kDa subunit) from rabbit skeletal muscle
was purchased from Sigma (P4533). Alternatively, an m-calpain prep-
aration from rabbit skeletal muscle kindly provided by Dr. T. Saido
[16] was used in some experiments with identical results. Peptides
NAKWDTGENPIYKSAVT, CEKEKM, CKWDTG, CSAVTT,
and CVTTVV corresponding to regions in the integrin L1 cytoplasmic
domain were synthesized using an Applied Biosystem Model 430A
automated peptide synthesizer and puri¢ed by reverse phase HPLC.
Masses of all synthetic peptides were veri¢ed by ion-spray mass spec-
trometry.
2.2. Recombinant cytoplasmic domain constructs
Cloning and recombinant production of model peptides represent-
ing the cytoplasmic domains of integrins is described in detail
elsewhere [15]. Brie£y, synthetic oligonucleotides were used in polym-
erase chain reactions (PCR) to create a cDNA for the heptad repeat
protein sequence KLEALEGRLDALEGKLEALEGKLDALEG
( = [heptad]4). This cDNA was ligated into a modi¢ed pET15b vector
(Novagen) and joined to cDNAs coding for cytoplasmic integrin do-
mains. The ¢nal constructs coded for the N-terminal sequence
GSSHHHHHHSSGLVPRGSHMCG[heptad]4 linked to the cytoplas-
mic domains of human integrin chains. Recombinant expression in
BL21(DE3)pLysS cells (Novagen) and puri¢cation of the recombinant
products were performed according to the pET System manual (No-
vagen) with an additional ¢nal puri¢cation step on a reverse phase
C18 HPLC column (Vydac).
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2.3. Antibodies
A polyclonal goat antiserum against the human integrin L1 chain
(Goat# 172), and rabbit sera against a synthetic integrin L1 cytoplas-
mic domain peptide (Rabbit# 60) and the integrin L3 calpain cleavage
fragment AKWDT [12] have been described. To produce antibodies
against speci¢c calpain cleavage sites in the integrin L1 cytoplasmic
domain we followed the protocol described in [12]. Brie£y, synthetic
hexapeptides corresponding to the C-termini of cleavage products
were conjugated via N-terminal cysteines to keyhole-limpet hemocya-
nin (Sigma) using m-maleimidobenzoyl-N-hydroxysuccinimide ester
(Pierce). Conjugates were used to immunize rabbits and resulting
sera were a⁄nity puri¢ed using these peptides coupled to Sulfolink
coupling gel (Pierce). In ELISA-type assays we con¢rmed the immu-
noreactivity and speci¢city of these antibodies for the corresponding
hexapeptides, as well as for peptide fragments generated in calpain
digests of the integrin L1 model protein (data not shown).
2.4. Calpain cleavage site mapping using synthetic and recombinant
peptides of integrin cytoplasmic domains
The recombinant model proteins of the cytoplasmic domains of
integrins (Fig. 1) were digested at 12 WM with puri¢ed m-calpain
(80 kDa subunit) (75 nM; 31 U/mg) for 0, 10, 30 and 360 min at
Fig. 1. Reverse phase HPLC of calpain digests obtained with the integrin L1 tail model protein obtained 0, 10, 30, and 360 min after calpain
addition. UV absorption at 208 nm was monitored during elution with a 5^60% acetonitrile/water gradient. Peptides identi¢ed in the peaks a^j
are listed in Table 1 and Fig. 2. The small peptide NPKYEGK, which must have been generated during the proteolysis, probably eluted in the
£ow-through (not shown), which was not analyzed by mass spectrometry because of its high salt content. The corresponding cleavage reaction
was identi¢ed by detection of the corresponding larger polypeptide fragment (GSTAVTTVV) (j) eluting at the end of the gradient in the large
peak shown on the right. This peak was collected into several fractions to allow the identi¢cation of large cleavage products (f^j) and uncleaved
recombinant protein. The peptide found in peak b (GSSHHHHHH-SSGLVPRG) resulted from cleavage in the N-terminal His-tag region. As-
terisks mark peaks corresponding to unidenti¢ed components, which were present in the digestion bu¡er prior to calpain addition.
Table 1
Calpain cleavage products of the recombinant integrin L1 cytoplasmic domain
Cleavage sitea Time (min)b Measured mass Predicted Assigned sequencec
V791 10 10 026 10 026.5 (j) GSöVTTVV
T789 10 9 828 9 828.2 (i) GSöSAVTT
10 1 034 1 034.2 (a) VVNPKYEGK
G778 s 30 8 623 8 623.9 (h) GSöKWDTG
s 30 1 223 1 223.4 (cP) GENPIYKSAVTT
T777 s 30 8 566 8 566.8 (g) GSöAKWDT
s 30 1 223 1 223.4 (c) ENPIYKSAVTT
M771 30 7 852 7 852.1 (f) GSöEKEKM
30 3 011 3 011.4 NAKWöKYEGK
s 30 2 193 2 194.4 (e) NAKWöVTTVV
30 1 995 1 996.2 (d) NAKWöSAVTT
The recombinant model protein of the integrin L1 cytoplasmic domain was digested with calpain (E/S = 1/160) at room temperature for 10,
30 and 360 min. Reaction products were separated by reverse phase HPLC and their masses measured by electrospray mass spectrometry as de-
scribed in the methods.
aL1 residue; numbering of amino acids relates to the human integrin chain sequence including its signal peptide.
bTime of ¢rst appearance of the peptide.
cLetters in parentheses relate to the peptide identi¢cation as depicted in Fig. 2. The dashes indicate intervening sequence omitted for clarity.
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room temperature in 50 mM HEPES, pH 7.2, 150 mM NaCl, 1 mM
CaCl2, 1 mM DTT. Reactions were stopped by addition of 5 mM
EDTA and 12 Wg/ml leupeptin. Each sample was separated by re-
versed phase HPLC and peak fractions were analyzed by electrospray
mass spectrometry on an API-III quadrupole spectrometer (Sciex,
Toronto, Ont., Canada). Sequences were assigned to proteolytic frag-
ments using the program MacProMass (Terry Lee, City of Hope,
Duarte, CA, USA) on the basis of the known sequence of the undi-
gested peptide and the determined molecular masses of the fragments.
For some of the smaller peptides, two to three possible peptide se-
quences were calculated. In these cases correct sequences could be
assigned by identi¢cation of the corresponding larger cleavage
products detected in the protein peak eluting at the end of the aceto-
nitrile gradient. In the case of the L1 integrin cytoplasmic domain,
additional calpain cleavage analysis was performed using the synthetic
peptide NAKWDTGENPIYKSAVT and a recombinant L1 peptide
with the sequence GIHPAHHKRGMCG[heptad]4KLLMIIHDRR-
EFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK. In
these experiments we detected identical major cleavage sites as shown
in Table 1.
2.5. Calpain cleavage in platelets and Jurkat cells
Platelets were separated from freshly drawn blood by centrifugation
at 200Ug for 20 min. Platelet-rich plasma was centrifuged at 1400Ug
for 15 min and sedimented platelets were washed twice in 0.12 M
NaCl, 0.013 M Na3citrate, 0.033 M D-glucose, pH 6.5. Washed plate-
lets were washed once more in HEPES-saline (3.8 mM HEPES, pH
7.3, 137 mM NaCl, 2.7 mM KCl, 5.6 mM D-glucose, 3.3 mM sodium
phosphate) and resuspended in this bu¡er with 1 mM CaCl2 at 1U109
platelets/ml. In an aggregometer after equilibration to 37‡C, calcium
ionophore A23187 (1 WM) (Sigma), thrombin (1 U/ml) and other
agents were added under stirring conditions for various lengths of
time. Platelets were solubilized by the addition of 1 volume 2-fold
concentrated sample bu¡er for SDS polyacrylamide electrophoresis
containing 0.1 mM E64, 10 Wg/ml leupeptin, 1 mM PMSF1 and
5 mM EDTA and heated to 110‡C for 5 min. Samples were run on
4^20% SDS polyacrylamide gels (NOVEX) and transferred to poly-
vinylidene di£uoride membranes (Millipore Corp., Bedford, MA,
USA). To ensure e⁄cient transfer of proteins, membranes were rou-
tinely stained with Ponceau S prior to blocking with 5% non-fat dry
milk in 50 mM Tris-Cl, pH 7.4, 0.15 M NaCl (TBS milk). Blots were
washed with TBS, 0.05% Tween-20 and antibodies added in TBS
milk. Detection of bound antibodies was performed with peroxi-
dase-conjugated goat anti-rabbit or anti-mouse antibodies (BIO-
SOURCE), which were visualized with an enhanced chemilumines-
cence kit (ECL, Amersham Corp.).
Jurkat cells were washed twice with PBS and then incubated in 20
mM HEPES, pH 7.4, 150 mM NaCl, 1 mg/ml D-glucose, 1 mg/ml
BSA, 10 mM CaCl2 at 4U107 cells/ml with or without 10 WM calcium
ionophore A23187 for 10 min at 37‡C. After short centrifugation, cells
were resuspended in the same bu¡er and lysed with sample bu¡er for
SDS polyacrylamide gel electrophoresis as described above for plate-
lets.
3. Results
After our initial demonstration of calpain-mediated proteo-
lysis of integrin L3 cytoplasmic domains in vitro and in vivo
[12], we asked whether susceptibility to cleavage by calpains is
a general property of integrin cytoplasmic domains. We used
the puri¢ed catalytic subunit of m-calpain to digest recombi-
nant protein models of integrin tails in vitro. These model
proteins consist of human integrin cytoplasmic tails linked
at their N-termini to a His-tag sequence and heptad repeat
Fig. 2. Calpain cleavage sites and fragments of the recombinant in-
tegrin L1 cytoplasmic domain model protein generated in vitro. Sin-
gle lower case letters refer to the identi¢ed peptides as shown in
Fig. 1 and Table 1.
Fig. 3. A: Western blot analysis of cell lysates obtained from human platelets stirred in the absence (3) or presence of either 1 WM calcium
ionophore A23187 (Io) for 2 min or of 1 U/ml thrombin (Thr) for 10 min at 37‡C. A: Loss of the L1 C-terminus was detected with polyclonal
antibodies reactive with the intact C-terminus of the L1 cytoplasmic domain (L1-C-Term). The presence of the extracellular domain of L1 was
also veri¢ed with an antibody against this region (L1-Extra). B: Detection of cleavages with polyclonal, a⁄nity-puri¢ed antibodies recognizing
individual cleavage sites in the L1 cytoplasmic domain (see Fig. 2). Due to the sequence similarity in L1 and L3 integrin tails (Fig. 5) the anti-
AKWDT777 antibody detected cleavage in both L1 and L3 cytoplasmic domains. Similarly, the serum raised against peptide KWDTG778 cross-
reacted with a homologous L3 fragment with the C-terminus KWDTA768. Although not reported previously [12], we now consistently observed
cleavage at this site after calpain digestion of recombinant integrin L3 cytoplasmic domain peptides in vitro (data not shown). An additional
band migrating slightly faster than L1 was observed with the antibodies that reacted exclusively with L1. It probably does not represent cleav-
age in the extracellular domain because it was also detected in undigested samples by antibodies against the C-terminus (A, Fig. 4). C: Analysis
of Jurkat cells treated with 10 WM calcium ionophore for 10 min.
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motifs forming a parallel dimeric coiled-coil (see Section 2)
[15]. They appear to mimic the native cytoplasmic domains
[15]. We digested the integrin L1 tail with calpain for 0, 10, 30
and 360 min and separated each digest by reverse phase
HPLC on an analytical C18 column (Fig. 1). Peak fractions
were analyzed by electrospray mass spectrometry. In addition,
we collected the major protein peak eluting in each digest at
the end of the 5^60% acetonitrile/water gradient (Fig. 1) into
several fractions, which were separately analyzed by mass
spectrometry. This allowed us to monitor larger peptide frag-
ments co-eluting with uncleaved protein in this peak. Table 1
lists the fragments obtained from the L1 integrin tail protein
model, which are schematically depicted in Fig. 2. Initial rapid
cleavage occurred at two sites in the membrane-distal region
(P1 residue = T789 and V791) as evidenced by the appearance of
peptides identi¢ed as a, i, and j in Figs. 1 and 2 and Table 1.
After 30 min of digestion cleavage occurred at a more prox-
imal site (P1 = M771) as evidenced by the appearance of pep-
tides d and f (Figs. 1 and 2, Table 1). In late (6 h) digests,
there was not intact protein remaining and two additional
minor cleavages were observed (P1 = T777, G778) as indicated
by the appearance of peptides c, cP, g, and h (Figs. 1 and 2,
Table 1). The 6 h digestion resulted in fragmentation in the N-
terminal His-tag region of the recombinant protein (Fig. 1,
peak b), however, the coiled-coil structures and the mem-
brane-proximal integrin sequences of the recombinant pep-
tides were not cleaved.
To analyze calpain cleavage of the L1 integrin tail in living
cells, we prepared a⁄nity-puri¢ed polyclonal antibodies
against each of its cleavage sites and used them on Western
blots of platelet lysates aggregated by treatment with the cal-
cium ionophore A21387 or with thrombin (Fig. 3). Ionophore
treatment resulted in nearly complete degradation of the L1
integrin cytoplasmic domain (Fig. 3A), and in the generation
of truncated fragments containing the C-termini VTTVV791,
ASVTT789, and KWDTG778. In contrast, those ending with
AKWDT777 or EKEKM771 were not detected (Fig. 3B).
Thrombin-induced aggregation resulted in partial degradation
of the L1 tail. Addition of E64d, a membrane-permeable spe-
ci¢c calpain inhibitor [1], or of EDTA to chelate calcium,
completely prevented the proteolysis (Fig. 4) con¢rming that
intracellular calpain was the responsible protease. We also
detected calcium-dependent proteolysis of L1 integrin tails in
ionophore-treated Jurkat cells (Fig. 3C).
To study possible calpain cleavage of other integrin cyto-
plasmic domains, we digested model proteins of integrin L1D,
L2, L3 and L7 tails with calpain in vitro (Tables 2^4, Fig. 5).
Cleavage of the recombinant integrin L3 cytoplasmic domain
occurred at sites reported previously [12] in addition to one
novel site (KWDTA768) (Fig. 5), which could be detected in
ionophore-treated platelets due to a cross-reaction of the anti-
bodies generated against the peptide KWDTG778 in the integ-
rin L1 tail (Fig. 3B). Cleavage sites obtained from the other
three L tails are listed in Tables 2^4 and the deduced cleavage
sites of all analyzed integrin cytoplasmic domains are sum-
marized in Fig. 5. In each case, cleavages were observed
around the two conserved NXXY motifs. These cleavage sites
manifested no other obvious conserved consensus sequence.
4. Discussion
The central ¢nding of this study is that calpains have the
potential to cleave most if not all integrin L tails at sites
£anking their conserved NPXY/NXXY motifs. Mutational
analysis of these motifs has established their importance in
regulating the a⁄nity of integrins for their ligands as well as
their capacity to localize to focal adhesion complexes
[13,14,17]. They are expected to introduce a unique structural
pattern into the integrin L tail due to their predicted tendency
Fig. 4. Calcium ionophore-induced calpain cleavage in platelets in
the absence and presence of the membrane-permeable calpain inhibi-
tor E64d (1 mM) or of EDTA (5 mM). Detection was performed
with sera recognizing cleavage fragments VTTVV791 and ASVTT789
or the C-terminus of the intact L1 cytoplasmic domain. Note that
the latter serum recognized the band migrating slightly faster than
the major integrin L1 chain protein. That band was also present in
the anti-VTVV and anti-SAVTT blots, but was cropped from the
images for clarity.
Table 2
Major calpain cleavage products of recombinant integrin L1D cytoplasmic domain
Cleavage sitea Time (min)b Measured mass Predicted mass Assigned sequencec
Y795 30 10 728 10 729.2 GSöKNPNY
30 896.5 987.0 NFKNPNY
K791 30 10 239 10 240.1 GSöINNFK
30 1 090 1 090.2 NPNYGRKAGL
F790 30 10 111 10 112.5 GSöPINNF
30 1 218.5 1 218.4 KNPNYGRKAGL
N789 10 9 964 9 965.4 GSöSPINN
30 1 365.0 1 365.6 FKNPNYGRKAGL
N788 10 9 850 9 851.3 GSöKSPIN
30 1 479.5 1 479.7 NFKNPNYGRKAGL
T777 30 8 566 8 566.8 GSöAKWDT
M771 30 7 850 7 851.1 GSöEKEKM
30 2 132 2 133.3 NAKWöSPINN
30 2 018.5 2 019.2 NAKWöKSPIN
See Table 1 for annotations.
For clarity, only the major, more rapidly generated fragments are indicated.
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to fold into tight L turns [14]. Moreover, residues in the ¢rst
NPXY motif of the integrin L1 tail are crucial for its binding
to the cytoskeletal proteins talin and ¢lamin [15,18]. Thus,
calpain cleavage of integrin cytoplasmic domains close to
these motifs is likely to disrupt integrin function and to
strongly compromise preexisting interactions with the cyto-
skeleton. Preliminary experiments using recombinant protein
models of integrin KIIb and K4 tails indicate that calpain
cleavage is a unique feature of integrin L and not K cytoplas-
mic domains (data not shown). This is again consistent with
the concept that calpains speci¢cally disrupt integrin cyto-
skeletal interactions, which are primarily established by the
L tails [19].
Our in vitro calpain cleavage analysis demonstrates most
rapid proteolysis of all tested L tails in at least one site located
between these motifs. Interestingly, the slight sequence varia-
tions between L1A, L2, L3 and L7 tails as well as the more
obvious sequence divergence between the L1A and L1D tails
in this short stretch do not alter its high sensitivity to calpain
cleavage (Fig. 5). Therefore, the susceptibility of integrin cy-
toplasmic domains to calpain cleavage is not primarily deter-
mined by the linear amino acid sequence at the scissile bonds,
but rather by the adjacent structural framework provided by
the NXXY motifs in the integrin L tails.
Our experimental approach to study calpain cleavage in
vitro with recombinant model proteins of integrin tails is val-
idated by a number of ¢ndings. Firstly, calpain digestion of
synthetic peptides and of di¡erent recombinant protein mod-
els of L1 and L3 cytoplasmic domains resulted in cleavage at
identical sites (this report, [12], and our unpublished observa-
tions). Secondly and more importantly, essentially all sites
determined in the L1 and L3 cytoplasmic domains in vitro,
were also generated by calpain proteolysis in aggregating
platelets with the exception of the most membrane-proximal
site (see also [12]). We have previously shown, that calpain
cleavage at this latter site requires platelet treatments leading
to the dissociation of integrin heterodimers [12]. This suggests,
that this cleavage site is not accessible in the intact integrin in
its cellular environment. Altogether, our data strongly indi-
cate that the calpain reactivity, which we monitored in vitro,
re£ects the potential of calpains to digest integrin cytoplasmic
domains in intact cells.
Calpain activation during platelet aggregation results in the
cleavage of a variety of proteins. For example, there is cleav-
age of talin, ¢lamin, pp125FAK, pp60src, p120cbl, and a 58
kDa protein cross-reacting with paxillin antibodies, which has
recently been identi¢ed as the paxillin-paralogue hic-5 [20]
(our unpublished observations, see also [1,6^8,21]). In con-
trast, thrombin-induced platelet aggregation induced only par-
tial, often barely detectable degradation of these proteins.
Thus, only limited proteolysis of speci¢c subsets of these pro-
teins occurs in the physiological situation rendering the detec-
tion of calpain reactivities rather di⁄cult. On the other hand,
platelets represent a relatively unique cell type, in which W-
calpains are present in excess compared to m-calpains and to
its natural inhibitor calpastatin [1]. Therefore, regulation of
calpain activity seems to di¡er in platelets and most nucleated
cells, where the levels of calpastatin, and W- and m-calpain are
more balanced. This might explain why, in our hands, cleav-
age of integrin L1 cytoplasmic domains and cytoskeletal pro-
teins in Jurkat cells required the presence of elevated concen-
trations of ionophore and calcium (data not shown).
The physiological signi¢cance of calpain-dependent proteo-
lysis still remains largely obscure. It has been suggested that
the cleavage of cytoskeleton-associated structures by calpain
during platelet aggregation results in dissociation of mem-
brane attachment sites from the actin cytoskeleton and inhib-
its ¢brin clot retraction [22]. In nucleated cells, the physiolog-
ical functions of calpains are even less clear. Our data ¢t well
into an emerging concept, in which calpains regulate integrin-
Table 3
Major calpain cleavage products of recombinant integrin L2 cytoplasmic domain
Cleavage sitea Time (min)b Measured mass Predicted mass Assigned sequencec
M762 10 10 040 10 039.4 GSöTTTVM
10 792.5 792.9 NPKFAES
F754 30 9 218 9 219.4 GSöDNPLF
K744 30 8 003 8 003.2 GSöKEKLK
30 2 055.5 2 055.3 SQWNöTTTVM
See Table 1 for annotations.
For clarity, only the major, more rapidly generated fragments are indicated.
Table 4
Major calpain cleavage products of recombinant integrin L7 cytoplasmic domain
Cleavage sitea Time (min)b Measured mass Predicted mass Assigned sequencec
T784 10 9978 9981.1 GSöSAITT
10 1598.5 1598.7 TINPöDSPTL
Y778 10 9378 9379.4 GSöSNPLY
10 2191 2191.4 KSAIöDSPTL
Q766 30 7889 7887.9 GSöEKEQQ
30 3677 3679.0 QLNWöDSPTL
30 2108.5 2108.4 QLNWöSAITT
Q765 30 7764 7763.7 GSöFEKEQ
30 3808 3807.2 QQLNöDSPTL
30 2237 2236.5 QQLNöSAITT
30 1635 1634.8 QQLNöSNPLY
See Table 1 for annotations.
For clarity, only the major, more rapidly generated fragments are indicated.
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dependent cytoskeletal organization [10]. This concept is sup-
ported by the subcellular localization of calpain [9] and of
calpain reactivity [23] in focal adhesion complexes, as well
as by the identi¢cation as calpain substrates of a large number
of proteins structurally or functionally implicated in focal
adhesion formation [1,6^8,10,12,24]. Moreover, recent studies
indicate that calpains are required for e⁄cient formation and
turnover of integrin-dependent focal adhesion complexes dur-
ing epithelial cell spreading and migration [25,26]. These cal-
pain activities might depend on £uctuations of intracellular
Ca2 levels, which have been observed in migrating neutro-
phils and reported to regulate the detachment of integrins
from their ligands [27,28].
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Fig. 5. Summary of the in vitro calpain cleavage sites identi¢ed in
this study using recombinant integrin L cytoplasmic domains. Ami-
no acid numbering relates to the sequences of human integrin L
chains including their signal peptides. Asterisks indicate conservative
modi¢cations of the original sequences (A725 to L in integrin L2,
and R747 to K in integrin L7), which have been introduced in the
recombinant proteins to preserve a HindIII restriction site.
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